DEFA14A: ESSA Pharma Details Tax Impact of XenoTherapeutics Deal

ESSA Pharma Inc. has mailed a letter to shareholders outlining the potential U.S. and Canadian federal income tax consequences of a cash distribution related to its business combination with XenoTherapeutics, Inc.

Summary

• ESSA Pharma Inc. is providing shareholders with information on the potential U.S. and Canadian federal income tax consequences of an initial cash distribution.
• This distribution is intended to occur prior to the closing of the previously announced business combination agreement with XenoTherapeutics, Inc. and XOMA Royalty Corporation.
• The distribution is part of the discontinuance and winding-up of ESSA Pharma's business.
• The distribution is subject to approval by the Supreme Court of British Columbia.
• For U.S. federal income tax purposes, the company intends to treat the distribution as part of a complete liquidation, generally resulting in capital gain or loss for U.S. Holders.
• For Canadian federal income tax purposes, the distribution is expected to be treated as a tax-free return of capital, reducing the adjusted cost base of shares, provided it does not exceed the paid-up capital and is part of a winding-up.

Sentiment

Score: 4

Explanation: The filing provides necessary information for shareholders regarding a significant corporate action (business combination and cash distribution). However, it highlights complex and potentially adverse tax implications, particularly for U.S. holders due to PFIC status and the uncertainty of IRS treatment. The lack of assurance on timing and amount of distribution, and the absence of third-party tax rulings, introduce elements of uncertainty and risk for shareholders.

Positives

• The company is proceeding with a cash distribution to shareholders as part of its business combination, indicating a clear path for shareholder return.
• The company expects the Canadian tax treatment of the distribution to be a tax-free return of capital for Resident Holders, which is generally favorable.

Negatives

• No assurance can be given regarding the amount or timing of the distribution, as it is subject to Court approval.
• The company believes it was classified as a Passive Foreign Investment Company (PFIC) for the taxable year ending September 30, 2024, and certain prior years, and expects to be classified as a PFIC for the current taxable year, which can lead to significant adverse U.S. tax consequences for U.S. Holders if certain elections are not made.
• There is no assurance that the IRS will agree with the company's conclusion to treat the distribution as part of a complete liquidation, which could result in the distribution being taxed as ordinary income with an additional interest charge for U.S. Holders.
• No third-party determination of paid-up capital or advance tax ruling has been sought or obtained regarding the Canadian tax treatment of the distribution.

Risks

• The proposed business combination may not be completed on anticipated terms or timing.
• Required securityholder, regulatory, and court approvals for the transaction and distribution may not be obtained.
• Conditions to the completion of the transaction may not be satisfied.
• Potential litigation relating to the transaction could be instituted by or against ESSA Pharma, XenoTherapeutics, Inc., XOMA Royalty Corporation, or their directors/officers.
• Disruptions from the transaction could harm ESSA Pharma's business, including current plans and operations.
• Ability to retain and hire key personnel may be impacted.
• Potential adverse reactions or changes to business relationships may result from the announcement or completion of the transaction.
• Continued availability of capital and financing and rating agency actions are uncertain.
• Legislative, regulatory, and economic developments could affect the business.
• Accuracy of financial projections is not guaranteed.
• General business, market, and economic conditions could be unfavorable.
• Certain restrictions during the pendency of the transaction may impact the company's ability to pursue business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events (e.g., terrorism, pandemics, war) could impact the company.
• Significant transaction costs are associated with the transaction.
• The transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the transaction could occur.
• U.S. Holders face adverse tax consequences if the IRS does not treat the distribution as a liquidating distribution, especially if ESSA Pharma is classified as a PFIC.
• Canadian tax treatment as a tax-free return of capital is not free from doubt and lacks third-party determination or advance ruling.

Future Outlook

The company anticipates completing the business combination and making a cash distribution to shareholders, subject to obtaining necessary securityholder, regulatory, and court approvals. The timing and amount of the distribution are not assured, and the company expects to be classified as a PFIC for the current taxable year, which may have significant tax implications for U.S. Holders.

Industry Context

This filing pertains to a specific corporate transaction (business combination and related cash distribution) for ESSA Pharma Inc., a company likely in the biotechnology or pharmaceutical sector given its name and the nature of its partner XenoTherapeutics. The tax implications discussed are standard considerations for cross-border corporate actions involving Canadian and U.S. entities, particularly when a company has a history of being a Passive Foreign Investment Company (PFIC).

Legal Proceedings

• Potential litigation relating to the transaction that could be instituted by or against the Company, XenoTherapeutics, Inc., XOMA Royalty Corporation or their respective directors or officers.

Stakeholder Impact

• Shareholders: Directly impacted by the cash distribution, its amount, timing, and significant U.S. and Canadian federal income tax consequences, including potential adverse effects from PFIC status and the need for tax planning.
• Employees: Potential impact on retention and hiring of key personnel due to business combination disruptions.
• Business Partners: Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction.

Next Steps

• Application to the Supreme Court of British Columbia for an Interim Order and Distribution Order, with a hearing scheduled for August 5, 2025.
• Shareholder vote regarding the Transaction (together with the Distribution and subsequent dissolution and liquidation of the Company).
• Filing of a definitive Proxy Statement with the SEC, which will be sent to securityholders.
• U.S. Holders may need to consider making a Qualified Electing Fund (QEF) election or mark-to-market election to mitigate adverse PFIC tax consequences.
• U.S. Holders may need to file IRS Form 8621 and IRS Form 8938.

Key Dates

Keywords

ESSA Pharma, XenoTherapeutics, Business Combination, Cash Distribution, SEC Filing, Tax Consequences, PFIC, Shareholder Letter, Corporate Action, Merger, Liquidation, Capital Reduction, Canadian Tax, US Tax